Business Overview
Exousia Bio, Inc. (formerly LAMY) is a clinical-stage biotechnology company developing therapeutic applications of exosomes, initially focused on oncology, following its acquisition of Exousia AI, Inc. on November 17, 2025. The company underwent a significant change in control and business direction during this period, transitioning from a financial education platform to a biotech development company. As of February 28, 2026, the company has not yet generated revenue from its biotech operations and remains in the development stage.
Segment Performance
The company has no reportable segments as of February 28, 2026. For the nine months ended February 28, 2026, the company reported a net loss of $50,897 compared to net income of $80,659 for the nine months ended February 28, 2025. Operating losses for the nine-month period were $268,818 in 2026 versus $6,882 in 2025, reflecting significant increases in research and development expenses ($161,426) and professional fees ($31,350) attributable to the acquisition and transition to biotech operations. The company generated minimal revenue of $3,750 in the prior year period with no revenue in the current period.
Key Risk Factors
The company faces substantial doubt about its ability to continue as a going concern, having accumulated a deficit of $288,623 from inception and lacking an ongoing revenue source to cover operating costs. Additional key risks include the company's limited operating history under its current business plan as a biotech company, dependence on obtaining additional capital from management and shareholders to meet minimal operating expenses, and the uncertainty of securing third-party equity or debt financing on acceptable terms. The company's success is contingent on executing its newly adopted Exousia AI business plan and navigating the complexities of clinical-stage biotechnology development.
